Lexicon Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexicon Pharmaceuticals (LXRX).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

4Buy

2Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$5Upside to Avg. PT+198.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$8
May 11, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$2→$3
Mar 23, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$6
Mar 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$2→$2
Mar 5, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$4→$6
Sep 2, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Aug 7, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$1→$2
Jun 24, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 28, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 7, 2025	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$10→$6
Mar 7, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Mar 7, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 4, 2025	Leerink Partners	Roanna Ruiz	Downgrade	Outperform→Market Perform	$1
Mar 3, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Mar 3, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Jan 29, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$4
Jan 29, 2025	Needham	Joseph Stringer	Maintained	Hold	—
Dec 23, 2024	Needham	Joseph Stringer	Maintained	Hold	—
Nov 25, 2024	Needham	Joseph Stringer	Maintained	Hold	—
Nov 22, 2024	Needham	Joseph Stringer	Maintained	Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

HC Wainwright & Co. analyst Joseph Pantginis maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $4 to $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Lexicon Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Lexicon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

People Also Watch

People Also Watch

Lexicon Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Lexicon Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROCantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PROCitigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PROHC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PROHC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PROHC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8

PRO
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target